These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 31846972

  • 21. [Indications and consequences of Helicobacter pylori eradication on gastroesophageal reflux disease].
    Gisbert JP, Piqué JM.
    Med Clin (Barc); 2005 May 14; 124(18):697-709. PubMed ID: 15899166
    [Abstract] [Full Text] [Related]

  • 22. Potent gastric acid inhibition in Helicobacter pylori eradication.
    Gisbert JP.
    Drugs; 2005 May 14; 65 Suppl 1():83-96. PubMed ID: 16335862
    [Abstract] [Full Text] [Related]

  • 23. Pharmacological management of GERD: where does it stand now?
    Hershcovici T, Fass R.
    Trends Pharmacol Sci; 2011 Apr 14; 32(4):258-64. PubMed ID: 21429600
    [Abstract] [Full Text] [Related]

  • 24. The rationale of acid suppression in the treatment of acid-related disease.
    Mohamed AH, Hunt RH.
    Aliment Pharmacol Ther; 1994 Apr 14; 8 Suppl 1():3-10. PubMed ID: 7910047
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
    Hori Y, Matsukawa J, Takeuchi T, Nishida H, Kajino M, Inatomi N.
    J Pharmacol Exp Ther; 2011 Jun 14; 337(3):797-804. PubMed ID: 21411494
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Treatment with proton pump inhibitors induces tolerance to histamine-2 receptor antagonists in Helicobacter pylori-negative patients.
    Qvigstad G, Arnestad JS, Brenna E, Waldum HL.
    Scand J Gastroenterol; 1998 Dec 14; 33(12):1244-8. PubMed ID: 9930386
    [Abstract] [Full Text] [Related]

  • 35. The Reduction in Gastric Atrophy after Helicobacter pylori Eradication Is Reduced by Treatment with Inhibitors of Gastric Acid Secretion.
    Niikura R, Hayakawa Y, Hirata Y, Ogura K, Fujishiro M, Yamada A, Ushiku T, Konishi M, Fukayama M, Koike K.
    Int J Mol Sci; 2019 Apr 18; 20(8):. PubMed ID: 31003453
    [Abstract] [Full Text] [Related]

  • 36. [New trends of acid-related diseases treatment].
    Koike T, Nakagawa K, Kanno T, Iijima K, Shimosegawa T.
    Nihon Rinsho; 2015 Jul 18; 73(7):1136-46. PubMed ID: 26165070
    [Abstract] [Full Text] [Related]

  • 37. [Mechanism of actions and clinical applications of proton pump inhibitors].
    Seol SY.
    Korean J Gastroenterol; 2006 Jul 18; 48(1):4-8. PubMed ID: 16861875
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders.
    Richardson P, Hawkey CJ, Stack WA.
    Drugs; 1998 Sep 18; 56(3):307-35. PubMed ID: 9777309
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.